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ABSTRACT 
Pressure ulcers are one of the major health care problems and results in a substantial 
amount of burden for both patients and health services. The aim of this study was to 
appraise effectiveness of topical Semelil (ANGIPARS™), a naive herbal extract, in 
pressure ulcers 
As a randomized controlled clinical trial, 18 patients with pressure ulcers were recruited 
from Vali-e-Asr hospital, Medical Sciences/ University of Tehran, Iran. Nine patients 
received topical Semelil (ANGIPARS™) during hospitalization and nine other patients 
received conventional treatment.  
Baseline characteristics of the topical and control groups did not differ across demographic, 
clinical and functional measures. The mean surface areas of the ulcers were reduced 48.2 ± 
85.3 cm2 (78.3%) and 2.8± 6.2 cm² (6.3%) in the treatment and control groups, respectively 
(p=0.000). 
From the results of this study it may be concluded that the use of topical Semelil 
(ANGIPARS™) with conventional treatment is more effective than those of only 
conventional treatment for patients with pressure ulcers. 
Keywords: ANGIPARS™, Pressure ulcer, Topical, Intervention 
 
INTRODUCTION 
The increased incidence of chronic and non-
contagious diseases has been one of the most 
important problems of health systems during the 
past decade. Today, a remarkable amount of 
burden is attributed to this group of disorders. One 
of the most important parts in estimation of 
disease burden is the disability resulting from the 
diseases such as injuries due to trauma, car 
accidents, brain vessel diseases, diabetes and 
osteoporosis. Induced bedsore in the above 
mentioned diseases and due to other reasons 
causes major problems and disabilities. 
Pressure ulcers have been associated with increase 
in mortality rates in both acute and long-term care 
settings. Death has been reported to occur during 
acute hospitalization in 67% of patients who 
develop a pressure ulcer compared with 15% of 
at-risk patients without pressure ulcers (1-2). 
Patients who develop a new pressure ulcer within 
6 weeks after hospitalization are three times more 
likely to die as patients who do not develop a 
pressure ulcer (3). 
In our country, in addition to above mentioned 
disorders, war victims bear a large amount of 
disabilities like spinal complications and 
amputation. It has been shown that bedsore is 
present in almost one third of war handicapped 
with spinal complications and most of them 
experience it during their life time(4). 
The normal response to tissue injury is a timely 
and orderly reparative process that results in 
sustained restoration of anatomical and functional 
integrity (5). In chronic wounds, the healing 
process is prolonged and incomplete, proceeds to 
an uncoordinated manner and results in a poor 
anatomical and functional outcome (6).  
There have been different methods for infection 
control and treatment of bedsore. Their main goal 
is to accelerate the wound healing and tissue 
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repair. All previous methods have only a partial 
effect on ulcer improvement and more effective 
therapies are essential. 
A novel treatment of wound healing is an herbal 
extract, Semelil (ANGIPARS™) (7) which has 
been studied in all steps of preclinical studies (8-
10). Approval of its efficacy and safety has been 
evaluated in three phases of clinical investigations 
and its capacity to accelerate ulcer healing was 
reported in recent studies (11-15).  
The aim of this clinical trial was to assess the 
therapeutic effects of topical Semelil 
(ANGIPARS™) in treatment of bedsore. 
 
MATERIAL AND METHODS 
We assigned a randomized, controlled trial over a 
period of one year (August 2006- August 2007) in 
Vali-e-Asr hospital, Medical Sciences/ University 
of Tehran (Iran). Eighteen patients were recruited 
according to the aforementioned criteria. All 
relevant data including patient age and weight, the 
longevity of the ulcer before our intervention, and 
the size, stage and location of the ulcer, were 
collected. Next, all the patients were examined to 
confirm their eligibility for the study. The 
eligibility criteria were: A) Inclusion Criteria: 
adult male and female subjects (with age more 
than 18 years) with bedsores. All patients with 
ulcers resulted from spinal complications 
(accidental or congenital), amputation of the 
lower limbs, chronic diseases like brain vessel 
disorders or fractures due to osteoporosis are 
included. Their ulcers sizes must be at least 1 cm2 
(measure of the longest length in longest width) 
with occurrence within the 2 last weeks in order to 
be enrolled in trial. After inclusion of each 
volunteer, complete information explained about 
the goal of the study, probable benefits and harms 
of the therapies and patients' rights during the 
research; and written informed consent was 
obtained. Patients voluntarily were enrolled the 
study. 
Exclusion criteria: All patients with acute 
infection of ulcer or any ulcer with bone exposure 
excluded. Other exclusion criteria was as follows: 
any other disease or situation that impairs ulcer 
improvement (such as malignancies, vasculitis, 
diabetes, connective  tissue diseases, Immunity 
system disorders, etc.) alcohol and drug abuse, 
dialysis and renal failure, corticosteroid 
consumption, the use of immune suppressive 
agents, radiotherapy, chemotherapy and any 
known drug hypersensitivity. 
After patient enrolment, primary assessments in 
addition to evaluation for inclusion and exclusion 
criteria were as follows: Exact inspection of the 
ulcer, measurement of its diameters and complete 
explanation of the ulcer features; photography, 
mapping and planimetry. 
Patients in intervention group received topical 
Semelil (ANGIPARS™) 3% gel daily and in 
control group received conventional treatment.  
Other procedures which carried out during the 
study were as follows: daily wound examination 
before drug administration renewal of the dressing 
by a physician, physical examination and taking 
history from patients, wound debridement 
between therapies according to physicians' 
diagnosis, photography and measurement of the 
ulcer diameters to assess any improvement, 
steadiness or regression per 2 weeks till 2 months, 
weekly documentation of patients' compliance and 
their acceptance, probable side effects. 
 
RESULTS 
Eighteen patients were treated via one of two 
methods. The mean age of the patients were 47.9 
± 21.2 years in intervention group and 46.6 ± 22.7 
years in control group. There were no significant 
differences among the two therapeutic groups in 
baseline demographic characteristics (Table 1).  
The alterations of ulcers surface areas and the 
degree of improvement in the two therapeutic 
groups are shown in (Table 2) 
Ulcer surface area in topical group was 56.1 ± 
93.3 at the first visit and after completion of the 
trial reduced to 7.8 ± 8.3 (p=0.008). On the other 
hand, in control group, ulcer surface area was 19.5 
± 16.1 at the beginning and after completing the 
trial decreased to 16.7 ± 13.6 (p=0.144). The 
mean percentages of reduction in surface 
comparing to the baseline size among intervention 
and control groups were: 78.3 ± 12.5 vs. 6.3 ± 
22.7, respectively (p=0.000). 
The improvement of healing, regardless of the 
location and stage, was better in the topical 
Semelil (ANGIPARS™) treatment group than in 
the conventional treatment (p=0.000). In the 
intervention group, 6 patients out of 9 (66.7%) 
had complete improvement in ulcer size and 3 
others (33.3%) had an acceptable healing of ulcers 
(Table 2). 
All patients completed the study and there were 
no losses to follow-up, no treatment withdrawals, 
no changes in trial group and no adverse events. 
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Table 1. Baseline characteristics of study subjects 
 ANGIPARS™  (n=9) Control  (n=9) P- value 
Age (year) 47.9 ± 21.2 46.0 ± 22.7 0.899 
Sex (M/F) 7/2 7/2 1.000 
Area of ulcer (cm2) 56.1 ± 93.3 19.5 ± 16.1 0.264 
Number of ulcer 1.2 ± 0.4 1.2 ± 0.7 1.000 
 
   
Table 2. Ulcer healing status in patients who used topical Semelil (ANGIPARS™) and control groups 
 ANGIPARS™  (n=9) Control (n=9) P- value 
Decrease in ulcer area (cm2)0.000 6.2 ± 2.8 85.3 ± 48.2 ٭ 
Decrease rate (%) 78.3 ± 12.5 6.3 ± 22.7 0.000 
Healing† > 80% 6 (66.7) 0 
 50-80% 3 (33.3) 1 (11.1) 
 20-50% 0 0 
 < 20% 0 8 (88.9) 
0.000 
 (%) Mean ± SD; † Number٭
 
DISCUSSION 
Pressure ulcers are extremely difficult to heal. 
Once they develop, this type of chronic wound is 
very resistant to any known medical therapy. 
Estimates of complete healing for pressure ulcers 
are as low as 10%. As less as 13% of pressure 
ulcers heals by 2 weeks in acute hospital settings 
(16, 17). In the younger patients with traumatic 
paraplegia, 74% of operated pressure ulcers were 
healed at discharge, 76% of patients were free of 
pressure ulcers. Within 10.9 months, 79% of 
operated ulcers recurred, and 79% of patients had 
additional pressure ulcers. Only 21% of traumatic 
paraplegics and 31% of nontraumatic 
nonparaplegic elderly patients remained healed 
after muscle-flap coverage for pressure ulcers 
(18). A decision analysis demonstrated that 
myocutaneous flap procedures for stage 3 of 
pressure ulcers were favorable unless the success 
rate for surgery was less than 30% or the healing 
rate with medical therapy was more than 40% 
(19). 
Lack of cellular and molecular signals required 
for normal wound repair processes such as 
resolution of inflammation, angiogenesis, 
deposition of extracellular matrix, contraction, 
epithelialization, and remodeling may be a major 
contributing factor to poor healing of chronic 
wounds such as pressure ulcers (20,21). 
Several types of topical wound treatments can 
promote more rapid epidermal resurfacing, as 
shown in controlled trials. Range of acceleration 
in healing varies from 18% to 36 % (22). 
Growth factors given topically including 
transforming growth factors alpha and beta, 
epidermal growth factor, platelet derived growth 
factor, fibroblast growth factor, interleukin-1, 
interleukin-2, and tumor necrosis factor alpha 
have been demonstrated to mediate the healing 
process. The concept of acceleration of healing in 
chronic wounds by using these acute wound 
factors is attractive. However, in trials in pressure 
ulcers, platelet derived growth factor failed to 
produce complete healing (23),although it did 
shorten the time to closure of wounds, as did basic 
fibroblast growth factor (24,25) The development 
of wound healing factor is still in its infancy but 
shows great promise 
Semelil (ANGIPARS™) is an herbal extract (7) 
and its capacity to accelerate ulcer healing was 
reported in recent studies (11-15). Since then, it 
has been used topically for wounds of diabetic 
foot ulcers in humans (15). Possible mechanisms 
of action of topical ANGIPARS™ on wound 
healing are increased angiogenesis. 
In this study, the therapeutic effects of topical 
ANGIPARS™ with usual treatment on pressure 
ulcers were shown to be superior to those of only 
usual treatment. In view of the cost of pressure 
ulcer management in hospitals and sanitariums 
and the high expenses of plastic surgery, it seems 
rational to shift to simpler methods that are more 
cost efficient and executable by the individual 
patients. The use of Semelil (ANGIPARS™) for 
treatment of pressure ulcers is less expensive and 
more comfortable and will ultimately increase the 
patients' self-confidence. 
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